FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 13:32:00 18/06/2024 BST | ||
| 52.84 EUR | -1.09% |
|
| Current month | -7.42% | ||
| 1 month | +49.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
| Date | Price | Change |
|---|---|---|
| 18/06/24 | 52.84 | -1.09% |
| 17/06/24 | 53.42 | -0.28% |
| 14/06/24 | 53.57 | +9.66% |
| 13/06/24 | 48.85 | +18.94% |
| 12/06/24 | 41.07 | +4.13% |
Delayed Quote Deutsche Boerse AG
Last update June 18, 2024 at 01:32 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SH8QA8 |
| ISIN | DE000SH8QA87 |
| Date issued | 13/04/2022 |
| Strike | 76.49 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 66.99 € |
|---|---|
| Lowest since issue | 2.72 € |
| Spread | 1.89 € |
| Spread % | 3.43% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.97
USD
Average target price
53.19
USD
Spread / Average Target
+29.84%
- Stock Market
- Certificates
- Certificat